Merestinib
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bone Metastases
Conditions
Bone Metastases, Breast Cancer
Trial Timeline
Jan 11, 2018 → Jun 24, 2019
NCT ID
NCT03292536About Merestinib
Merestinib is a phase 1 stage product being developed by Eli Lilly for Bone Metastases. The current trial status is terminated. This product is registered under clinical trial identifier NCT03292536. Target conditions include Bone Metastases, Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03292536 | Phase 1 | Terminated |
| NCT02920996 | Phase 2 | Terminated |
| NCT02779738 | Phase 1 | Completed |
Competing Products
20 competing products in Bone Metastases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Denosumab + Zoledronic Acid | Daiichi Sankyo | Phase 3 | 77 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Enzalutamide | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus | Astellas Pharma | Phase 2 | 52 |
| FORTEO + Placebo | Eli Lilly | Phase 1 | 33 |
| Arzoxifene + Placebo | Eli Lilly | Phase 3 | 77 |
| Tanezumab | Eli Lilly | Phase 3 | 77 |
| Anastrozole + Tamoxifen | AstraZeneca | Phase 3 | 77 |
| zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic acid + Letrozole | Novartis | Phase 3 | 77 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Phase 1 | 33 |
| Reclast (ZOL446, zoledronic acid) | Novartis | Approved | 85 |
| Zoledronic acid | Novartis | Phase 3 | 77 |
| Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid | Novartis | Phase 3 | 77 |
| zoledronic acid | Novartis | Phase 1 | 33 |
| Ruxolitinib continuous therapy | Novartis | Phase 2 | 52 |
| zoledronic acid | Novartis | Approved | 85 |